ZN-c3 is an orally active, highly potent and selective Wee1 inhibitor (IC50=3.9 nM). ZN-c3 can be used for the research of cancer[1].
ZN-c3 IC50 is 103 nM in H23c cells[1].
ZN-c3 (80 mg/kg; p.o.; 28 days) can effectively shrank tumors at 80 mg/kg as a single agent[1].ZN-c3 shows excellent exposures and bioavailability in the dog PK study[1].
[1]. Huang PQ, et al. Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer [published online ahead of print, 2021 Aug 23]. J Med Chem. 2021;10.1021/acs.jmedchem.1c01121.